Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, parallel-group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TEMSO
  • Sponsors Sanofi

    • Most Recent Events

    • 27 Apr 2023 Results 3D conformational analysis of MP-RAGE images from the TEMSO trial , presented at the 75th Annual Meeting of the American Academy of Neurology 2023
    • 19 Sep 2022 Results of post-hoc analysis of two studies (TEMSO; NCT00134563 & long-term extension NCT00803049) assessing relationship between teriflunomide's effects on brain volume loss and cognition, published in the Multiple Sclerosis Journal.
    • 28 Jun 2022 Results of post-hoc analysis of two studies (TEMSO (NCT00134563) and TOWER (NCT00751881)) assessing effect of teriflunomide on various dGM structures, presented at the 8th Congress of the European Academy of Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top